Anti-BAFFR Monoclonal Antibody ESG206 clinical trials
Also written ESG206.
Its developmentBy Shanghai Escugen Biotechnology, step by step5 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-BAFFR Monoclonal Antibody ESG206 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-BAFFR Monoclonal Antibody ESG206 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Shanghai Escugen Biotechnology Co., Ltd (5)
Studies
Open first, then newest update. How each study uses Anti-BAFFR Monoclonal Antibody ESG206 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus ErythematosusNot yet recruitingPhase 2Shanghai Escugen Biotechnology Co., LtdNCT07760155Written as ESG206
- A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren SyndromeNot yet recruitingPhase 2Shanghai Escugen Biotechnology Co., LtdNCT07375524Written as ESG206
- A Phase 1/2 Study of ESG206 in Patients With Primary Immune ThrombocytopeniaRecruitingPhase 1/2Shanghai Escugen Biotechnology Co., LtdNCT06853444Written as ESG206
- A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid MalignanciesCompletedPhase 1Shanghai Escugen Biotechnology Co., LtdNCT05822843Written as ESG206
- A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid MalignanciesWithdrawnPhase 1Shanghai Escugen Biotechnology Co., LtdNCT05263739Written as ESG206